go-v.orgdoi

Immunotherapy and cancer – making the past prologue

Susan F. Slovin · Clinical Investigation · 2012

  • DOI 10.4155/cli.12.82
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2012

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2012

Abstract

The goals of all novel therapies include improvement in overall survival, quality of life and disease control. We are fortunate to finally have two therapies that have demonstrated survival benefit in Phase III clinical trials – one, ipilimumab, a monoclonal antibody against CTLA-4, a checkpoint inhibitor, and the other, Sipuleucel-T, an autologous-based cellular therapy. Ipilimumab is the second drug that has been approved for melanoma within the last year, suggesting that there are multiple ways to achieve antitumor responses.

Sipuleucel-T is the first immunotherapy approved for asymptomatic, castration-resistant prostate cancer, and while Sipuleucel-T lengthened survival modestly, there was no improvement in time to progression and no responders. While Sipuleucel-T has been well-tolerated, ipilimumab has been associated with autoimmune-related events. As single agents, these drugs have shown benefit; however, maximizing durability remains a challenge. This article provides support for our continued eff...

Open the resolved locator · 10.4155/cli.12.82

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 01:31 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.12.82
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.